Acute hyperinsulinaemia decreases hepatic secretion of very low-density lipoprotein apolipoprotein B-100 in normolipidaemic, non-diabetic subjects

Endocrinology and Metabolism, Supplement

Volumn 3, Issue 4, 1996, Pages 253-263

  Watts, Gerald F ^a   Cummings, Michael H ^b   Kelly, Joanne M ^a   Umpleby, Margot ^a   O'Brien, Sheila F ^b   Sönksen, Peter H ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; MEVALONIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029807026     PISSN: 1074939X     EISSN: 20935978     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Young S. Recent progress in understanding apolipoproteinB. Circulation 1989; 80: 219-333.
2. Gibbons GF. Assembly and secretion of hepatic very-low-density lipoproteins. Biochem. J. 1990; 268: 1-13.
3. Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 1993; 13: 629-636.
4. Bonadonna RC, Groop LC, Zych K, Shauk M, De Fronzo RA. Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am. J. Physiol. 1990; 259: E736-E750.
5. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J. Lipid Res. 1994; 35: 177-193.
6. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta 1994; 1215: 9-32.
7. Durrington P. Is insulin atherogenic? Diabetic Med. 1992; 9: 587-600.
8. Topping DL, Mayes PA. Insulin and non-esterified fatty acids. Acute regulators of lipogenesis in perfused rat liver. Biochem. J. 1982; 204: 433-439.
9. Sparks CE, Sparks JD, Bolognino M, Salhanick A, Strumph PS, Amatruda JM. Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes. Metabolism 1986; 35: 1128-1136.
10. Reaven GM, Greenfield MS. Diabetic hypertriglyceridaemia. Evidence for three clinical syndromes. Diabetes 1981; 30: 66-75.
11. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridaemia. Am. J. Med. 1974; 57: 551-560.
12. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinaemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993; 42: 833-842.
13. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J. Clin. Invest. 1995; 95: 158-166.
14. Shumak SL, Zimman B, Zuniga-Guarjardo S, Poapst M, Steiner G. Triglyceride-rich lipoprotein metabolism during acute hyperinsulinemia in hypertriglyceridemic humans. Metabolism 1988; 37: 461-466.
15. Shaefer JR, Rader DJ, Brewer BN. Investigation of lipo-protein kinetics using endogenous labelling with stable isotopes. Curr. Opin. Lipidol. 1992; 3: 227-232.
16. Watts GF, Naoumova R, Cummings MH, Umpleby AM, Slavin MB, Thompson GR. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidaemic subjects. Metabolism 1995; 44: 1-7.
17. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM, Thompson GR, Sönksen PH. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995; 38: 959-967.
18. Cummings MH, Watts GF, Pal C, Umpleby M, Hennessy TR, Naoumova R, Sönksen PH. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-110 in obesity: a stable isotope study. Clin. Sci. 1995; 88: 225-233.
19. Watts GF, Cummings MH, Umplby M, Quiney JR, Naoumova R, Thompson GR, Sönksen PH. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest. 1995; 25: 559-567.
20. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EM, Alberts AW, Tobert J, Chen J, De Skipper PJ. Plasma mevalonate as a measure of cholesterol biosynthesis in man. J. Clin. Invest. 1984; 74: 795-804.
21. Durrington PN. Normal serum lipid and lipoprotein concentrations. In: Durrington PN. Hyperlipidaemia. Diagnosis and Management. London: Wright, 1989: 56-86.
22. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979; 237: E214-E223.
23. Porte D, Bierman EL The effect of heparin infusion on plasma triglyceride in vivo and in vitro with a method for calculating triglyceride turnover. J. Lab. Clin. Med. 1969; 73: 631-648.
24. Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sönksen PH. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis 1995; 113: 79-89.
25. Kane JP, Sata T, Hamilton RL. Apoprotein composition of very low density lipoproteins of human serum. J. Clin. Invest. 1975; 56: 1622-1634.
26. Cobelli C, Toffolo G. Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 1992; 262: E968-E975.
27. Cummings MH, Watts GF, Lumb PJ, Slavin BM. Comparison of immuno-turbidimetric and Lowry methods for measuring concentration of very-low-density lipoprotein apolipoprotein B-100 in plasma. J. Clin. Path. 1994; 47: 176-178.
28. Pfohl M, Naoumova RP, Class C, Knisel W, Jakober B, Risler T, Thompson GR. Acute and chronic effects on cholesterol synthesis of LDL-apheresis with and without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 1994; 35: 1946-1955.
29. Henderson AD, Richmond W, Elkeles RS. Hepatic and lipoprotein upases selectively assayed in post heparin plasma. Clin. Chem. 1993; 39: 218-223.
30. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphisms and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.
31. Foster DM, Barrett PHR, Toffolo G, Beltz WF, Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J. Lipid Res. 1993; 34: 2193-2205.
32. ICSH. Recommended methods of measurement of red-cell and plasma volume. J. Nuclear Med. 1980; 21: 793-812.
33. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Kelly JM, Jackson NC, Sönksen PH. Acute hyperinsulinaemia decreases hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in non-insulin dependent diabetes mellitus. Diabetes 1995; 44: 1059-1065.
34. Bartlett SM, Gibbons GF. Short- and longer-term regulation of very-low-density lipoprotein secretion by insulin, dexamethasone and lipogenic substrates in cultured hepatocytes. A biphasic effect of insulin. Biochem. J. 1988; 249: 37-43.
35. Pietri AD, Dunn EL, Grundy SM, Raskin P. The effect of continuous insulin infusion on very-low-density lipoprotein triglyceride metabolism in type 1 diabetes mellitus. Diabetes 1983; 32: 75-81.
36. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B- continuing lipoproteins in NIDDM. Diabetes 1990; 39: 1017-1026.
37. Malmstom R, Watson TOG, Stewart PJ, Rannikko S, Packard CJ, Shepherd J, Taskinen MR. Regulatory sites of acute insulin action on very low density (VLDL) apolipoprotein B subclass metabolism. (Abstract). Diabetologia 1995; 38 (Suppl. 38): A247.
38. Yki-Jarvinen H, Taskinen MR, Koivisto VA, Nikkila EA. Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man. Diabetologia 1984; 27: 364-369.
39. Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. Determination of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J. Lipid Res. 1991; 32: 1311-1323.
40. Lichtenstein AM, Cohen JS, Hackley DL, Millar JS, Ordovas JM, Schaefer EJ. Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-1 and B-100 kinetics. J. Lipid Res. 1990; 31: 1693-1701.
41. Foster DM, Barrett PHR, Toffolo G, Beltz WF, Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J. Lipid Res. 1993; 34: 2193-2205.
42. Zak R, Martin AF, Blough R. Assessment of protein turnover by use of radioisotopic tracers. Physiol. Revs. 1979; 59: 407-447.
43. Fern EB, Garlick PJ. The specific radioactivity of the tissue free amino acid pool as a basis for measuring the rate of protein synthesis in the rat in vivo. Biochem. J. 1974; 142: 413-419.
44. 13C] leucine infusion in normal volunteers. Eur. J. Clin. Invest. 1993; 23: 602-614.
45. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976; 12: 563-571.
46. Parker TS, McNamara DJ, Brown C, Garrigan D, Kolb R, Batwin M, Ahrens EM Jr. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc. Natl. Acad. Sci. USA 1982; 79: 3037-3041.
47. Pullinger CR, North JD, Teng BB, Rifici VA, Ronhild de Brito AE, Scott J. The apolipoprotein B gene is constitively expressed in HepG2 cells; Regulation of secretion by oleic acid, albumin, and insulin and measurement of the mRNA half-life. J. Lipid Res. 1989; 30: 1065-1077.
48. Bjornsson OG, Duerden JM, Bartlett SM, Sparks JD, Sparks CE, Gibbons GF. The role of pancreatic hormones in the regulation of lipid storage, oxidation and secretion in primary cultures of rat hepatocytes. Biochem. J. 1992; 281: 381-386.
49. Adeli K, Theriault A. Insulin modulation of human apolipoprotein B mRNA translation: studies in an in vitro cell-free system from HepG2 cells. Biochem. Cell Biol. 1992; 70: 1301-1312.
50. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J. Biol. Chem. 1990; 265: 8854-8862.
51. Umpleby AM, Sönksen PH. The chalonic action of insulin in man. In: Garrow JS, Hallidy D (eds). Substrate and Energy Metabolism. London: John Libby, 1985; 167-178.
52. Ida Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM. Differences in postprandial lipemia between patients with normal glucose tolerance and non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1993; 76: 172-177.
53. Zilversmit DB. Atherogenesis: a postprandial phenomena. Circulation 1979; 60: 473-485.